# Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke

> **NCT05748587** · — · COMPLETED · sponsor: **Aswan University Hospital** · enrollment: 48 (actual)

## Conditions studied

- Brain Ischemia

## Interventions

- **DIAGNOSTIC_TEST:** Serum Iron
- **DIAGNOSTIC_TEST:** RBCs Alpha-synuclein
- **DIAGNOSTIC_TEST:** Serum Soluble lymphocyte activation gene
- **RADIATION:** Brain computed tomography
- **DIAGNOSTIC_TEST:** Brain Iron
- **DIAGNOSTIC_TEST:** Brain Alpha-synuclein
- **DIAGNOSTIC_TEST:** Brain lymphocyte activation gene
- **DRUG:** Deferoxamine

## Key facts

- **NCT ID:** NCT05748587
- **Lead sponsor:** Aswan University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05748587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05748587, "Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05748587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*